Medium materiality5/10
KeyBanc upgrades Maravai LifeScience to Overweight
Why it may matterVerify against the original reporting
The upgrade and sizable stated upside are bullish, though this is a single analyst opinion.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
KeyBanc upgraded MRVI to Overweight and set an $11 target, about 43% above the reported $7.70 price.
- KeyBanc upgrade to Overweight; $11 target versus $7.70 posted price.
Key facts
- 01
Target: $11
- 02
Posted price: $7.7
- 03
Analyst firm: KeyBanc
- 04
Analyst: Paul Knight
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.